Stock Market Most Active AMEX Stocks Tuesday, January 21, 2014

New Post Public Reply Private Reply Replies (0) Message Board
Polgar
AMEX Most Active 

SYMBOL NAME PRICE ($) CHANGE % CHANGE VOLUME
SPY SPDR S&P 500 184.10 +0.47 +0.25%  55,380,349
EEM iShares MSCI Emerging Index Fund 39.74 -0.05 -0.11%  31,493,119
XLF SPDR Select Sector Fund - Financial 21.94 +0.01 +0.05%  31,383,418
GDX Market Vectors Gold Miners ETF 23.65 +0.32 +1.37%  22,265,757
IWM iShares Russell 2000 ETF 116.51 +0.58 +0.50%  15,463,374
IMUC Immunocellular Therapeutics 1.39 +0.23 +19.83%  14,911,946
VXX iPath S&P 500 VIX Short-Term Futures ETN 40.85 -0.28 -0.68%  14,447,846
FXI iShares FTSE China 25 Index Fund 35.78 -0.02 -0.06%  13,782,491
EWJ iShares MSCI Japan Index Fund 12.06 +0.01 +0.08%  13,630,661
VWO Vanguard FTSE Emerging Markets ETF 39.31 -0.13 -0.33%  12,667,346
EFA iShares MSCI EAFE ETF 67.02 +0.21 +0.31%  11,091,814
HEB Hemispherx BioPharma Inc 0.47 +0.06 +13.70%  10,838,153
EWZ iShares MSCI Brazil Capped Index Fund 41.58 -0.63 -1.49%  9,595,642
ONVO Organovo Hldgs Inc 10.20 -0.95 -8.51%  8,690,020
TZA DIREXION DLY SM CAP BEAR 3X 16.39 -0.24 -1.44%  7,967,755
XLI SPDR Select Sector Fund - Industrial 51.84 +0.02 +0.03%  7,202,900
RNN Rexahn Pharmaceuticals Inc 1.09 -0.01 -0.91%  7,160,039
SLV iShares Silver Trust 19.15 -0.37 -1.87%  6,586,780
UVXY ProShares Trust Ultra VIX Short Term Futures ETF 15.34 -0.20 -1.29%  6,502,254
XLE SPDR Select Sector Fund - Energy Select Sector 86.66 +0.65 +0.76%  6,148,882
MSTX Mast Therapeutics Inc 0.93 +0.08 +9.39%  6,104,682
DIA SPDR Dow Jones Industrial Average ETF 163.77 -0.31 -0.19%  5,900,356
SDS ProShares UltraShort S&P500 29.81 -0.16 -0.54%  5,664,870
XLY SPDR Select Sector Fund - Consumer Discretionary 65.03 -0.06 -0.09%  5,355,855
TNA Direxion Small Cap Bull 3x Shares 79.45 +1.20 +1.53%  5,308,706
NUGT Direxion Daily Gold Miners Bull 3X Shares 37.77 +1.61 +4.45%  5,181,210
LBMH Liberator Medical Hldgs Inc 5.08 -0.86 -14.48%  5,129,974
PAL North American Palladium Ltd. 0.66 +0.10 +17.57%  5,034,736
GLD SPDR Gold Trust 119.82 -1.11 -0.92%  5,031,966
DUST Direxion Daily Gold Miners Bear 3X Shares 30.15 -1.34 -4.26%  4,825,573
VTI Vanguard Total Stock Market ETF 95.95 +0.24 +0.26%  4,595,083
IYR iShares U.S. Real Estate ETF 65.07 +0.39 +0.60%  4,588,829
GSS Golden Star Resources Ltd. 0.61 +0.07 +14.03%  4,534,091
DGAZ VelocityShares 3X Inverse Natural Gas ETN linked to the S&P GSCI Natural Gas INd 7.69 -0.63 -7.62%  4,487,670
XLP SPDR Select Sector Fund - Consumer Staples 42.22 +0.15 +0.35%  4,182,743
OIH Market Vectors Oil Services ETF 47.43 +0.28 +0.59%  4,175,432
XLK SPDR Select Sector Fund - Technology 35.85 +0.10 +0.29%  4,130,768
XLU SPDR Select Sector Fund - Utilities 38.41 +0.35 +0.92%  4,058,455
ANV Allied Nevada Gold Corp. 5.03 +0.20 +4.14%  3,783,822
XLV SPDR Select Sector Fund - Health Care 57.28 +0.26 +0.46%  3,694,503
SSO ProShares Ultra S&P500 101.76 +0.52 +0.51%  3,649,590
DXJ WisdomTree Japan Hedged Equity Fund 50.25 +0.07 +0.14%  3,621,896
XLB Materials Select Sector SPDR 46.21 +0.28 +0.61%  3,521,438
KRE SPDR S&P Regional Banking ETF 40.88 +0.82 +2.05%  3,518,205
NGD New Gold Inc. 5.76 -0.05 -0.86%  3,428,752
SPXU ProShares UltraPro Short S&P500 15.18 -0.12 -0.78%  3,402,509
EWT iShares MSCI Taiwan Index Fund 14.03 -0.07 -0.50%  3,367,232
TLT iShares 20 Year Treasury Bond ETF 105.62 +0.14 +0.13%  3,352,921
DNN Denison Mines Corp. 1.42 +0.10 +7.58%  3,253,182
VGK Vanguard FTSEEuropean ETF 59.03 +0.34 +0.58%  3,179,243
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 387

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 544

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 109

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 305

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 161

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 411

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 174

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Breakthroughs in Lung Cancer Treatment with Reqorsa

Updated Category News Views 182

Innovative Advances in Lung Cancer Treatment The fight against lung cancer continues to evolve, showcasing promising advancements that bring new hope to patients. Genprex, Inc. is at the forefront of this battle with its revolutionary gene therapy known as Reqorsa. This cutting-edge treatment has been developed specifically to target KRAS mutation in non-small cell lung...

Continue Reading
EfTEN United Property Fund Reports October Earnings and NAV

Updated Category News Views 192

Insights into EfTEN United Property Fund's Recent Performance EfTEN United Property Fund demonstrated a net profit of 110 thousand euros for October, totaling 2.214 million euros for the first ten months of the year, marking a significant improvement from 724 thousand euros during the same period last year. This impressive financial outcome led to a distribution to...

Continue Reading
Cardiff Oncology Reports Encouraging Results in mCRC Trial

Updated Category News Views 236

Cardiff Oncology Reveals Promising Clinical Trial Results Cardiff Oncology, Inc. (Nasdaq: CRDF), a pioneering clinical-stage biotechnology company, has recently announced encouraging results from its ongoing CRDF-004 clinical trial. This randomized Phase 2 trial is investigating the effects of onvansertib in patients suffering from first-line RAS-mutated metastatic...

Continue Reading
Japan's Growing Casting Polyurethane Market and Its Future

Updated Category News Views 127

Japan's Casting Polyurethane Market: A Rising Force The Japan casting polyurethane market is on the verge of significant transformation, anticipated to elevate from a valuation of US$ 134.74 million to a remarkable US$ 248.24 million by 2033. This growth trajectory highlights a compelling compound annual growth rate (CAGR) of 7.08%, revealing the underlying strength...

Continue Reading
Hudson Technologies Faces Challenges Amid Downgrade by B.Riley

Updated Category News Views 353

B.Riley Downgrades Hudson Technologies Stock In a recent market statement, B.Riley has lowered its outlook on Hudson Technologies (NASDAQ: HDSN), shifting the stock rating from Buy to Neutral. This adjustment comes amidst new growth projections adjusted downwards from +16.6% to +8.5%. The modification in expectations has been linked to ongoing pressures on...

Continue Reading